Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 18/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.72 |
| ▸ | HTR3A | P46098 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31553435 | 1.00 | HRH1 (1.00) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| Water SCHEMBL10337970 | 0.99 | HRH1 (0.98) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL10337606 | 0.87 | HRH1 (0.77) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL11479448 | 0.85 | SSTR5 (0.81) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL10337607 | 0.85 | HRH1 (0.74) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL10337877 | 0.85 | HRH1 (0.74) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL5229655 | 0.85 | HRH1 (0.73) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL10337972 | 0.85 | HRH1 (0.73) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| SCHEMBL10483540 | 0.82 | HRH1 (0.70) | HRH1CYP2D6CHRM1KCNH2HTR3A | |
| Hydrochloric Acid SCHEMBL15567584 | 0.82 | HRH1 (0.69) | HRH1CYP2D6CHRM1KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1034978-A | — | — | None | — | — | JP | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-7355042-B2 | Treatment of CNS disorders using CNS target modulators | HYPNION, INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | disclosed |
| EP-1564212-B1 | PROCESS AND INTERMEDIATES FOR OBTAINING 1-(1H-BENZIMIDAZOL-2-YL)-4-(PYRIMIDIN-2-YLAMINO)PIPERIDINE DERIVATIVES | RAGACTIVES SL (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | RAGACTIVES, S.L. | 2005-10-13 | — | — | US | disclosed |
| EP-1564212-A1 | METHOD AND INTERMEDIA USED TO OBTAIN DERIVATIVES OF 1-(1H- BENZIMIDAZOLE-2-YL)-4-(2-AMINOPYRIMIDINE)PIPERIDINE | Ragactives, S.L. (ES) | 2005-08-17 | — | — | EP | disclosed |
| US-4912219-A | 2-[4-pyrimidin-2-yl amino)piperidin-1-yl]benzimidazole compound | SYNTHELABO (FR) | 1990-03-27 | — | — | US | disclosed |
| US-4857536-A | Antihistaminic benzimidazole derivatives | SYNTHELABO (FR) | 1989-08-15 | — | — | US | disclosed |
| US-4820710-A | ANTIALLERGENS, ANTIHISTAMINES, ANTIINFLAMMATORY AGENTS | SYNTHELABO (FR) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228006-A1 | Process and intermediates for obtaining 1-(1H-benzimidazol-2-YL)-4-(2-aminopyrimidine)piperidine derivatives | IL2, IL4, IL4I1 | HRH1 37/4885CYP2D6 177/4885CHRM1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.